SinoMab BioScience Ltd (03681.HK)価格

SinoMab Bioscience Ltd. is a clinical stage biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody-based biologics. The company employs 61 full-time employees The company went IPO on 2019-11-12. The firm primarily develops mAb-based biologics and new chemical entities (NCE) and its product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The firm is also developing drugs such as SM17, which has the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF) and other immune diseases, and SN1011, which targets systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).